Evidence map›Paper›PMID 40379352›Full record

ArticleBMJ open2025

Protocol for the economic evaluation of the Care for Adolescents who Received Information 'Bout Outcomes, 2nd iteration (CARIBOU-2) non-randomised, cluster-controlled trial of an integrated care pathway for depression in adolescents.

Claire de Oliveira, Joyce Mason, Bahar Amani, Gray Liddell, Peter Szatmari, Jo Henderson, Darren Courtney

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05142683 (Effectiveness of an Integrated Care Pathway for Adolescent Depression), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05142683 narecruitingnot on this map

Effectiveness of an Integrated Care Pathway for Adolescent Depression: A Quasi-experimental, Multi-site, Cluster Controlled Trial

TypeinterventionalSponsorCentre for Addiction and Mental HealthRan2022 to 2027Enrolled300ConditionsMajor Depressive DisorderArmsTreatment As Usual, CARIBOU-2
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Claire de OliveiraInstitute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada claire.deoliveira@camh.ca.ORCID http://orcid.org/0000-0003-3961-6008
Joyce MasonInstitute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Bahar AmaniCundill Centre for Child and Youth Depression, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Gray LiddellCundill Centre for Child and Youth Depression, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Peter SzatmariCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health , Toronto, Ontario, Canada.
Jo HendersonCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health , Toronto, Ontario, Canada.
Darren CourtneyCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health , Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0003-1491-0972

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDepressive disorders in adolescents are highly prevalent and debilitating and are a risk factor for self-harm and death by suicide. In the context of recovery from the COVID-19 pandemic, strained healthcare resources are compounded by an increased demand for treatment services for adolescents with depression. The objective of this study protocol is to delineate the proposed economic evaluation of an integrated care pathway for depression in adolescents within the Care for Adolescents who Received Information 'Bout Outcomes, 2nd iteration (CARIBOU-2) non-randomised, cluster-controlled trial. METHODS AND ANALYSIS: Two economic evaluations of the CARIBOU-2 trial (n=300) will be conducted-a cost-effectiveness analysis and a cost-utility analysis. In the cost-effectiveness analysis, we will examine the primary clinical outcome of the trial, change in the Mood and Feelings Questionnaire total score. In the cost-utility analysis, the clinical outcome will be quality-adjusted life-years, a generic measure of health burden. Data on the resources and respective costs required to deliver the intervention will be collected by the research team. Data on resource use post-intervention will be obtained from a mix of administrative data holdings and self-report; relevant unit costs will be obtained from existing data sources. The outcome of both economic evaluations will be the incremental cost-effectiveness ratio. Relevant sensitivity analyses will be undertaken, and cost-effectiveness acceptability curves will be produced to characterise any sources of uncertainty in the analysis. Equity considerations will also be examined, where relevant. ETHICS AND DISSEMINATION: Ethical approval for the larger CARIBOU-2 trial, including the economic evaluation, has been obtained by the Centre for Addiction and Mental Health as well as site-level ethics boards (019/2021; Centre for Addiction and Mental Health). All participants will provide informed consent for their data to be analysed and reported. The results of the main trial and the economic evaluation will be submitted for publication in a peer-reviewed journal and shared with relevant policy makers across Canada. TRIAL REGISTRATION NUMBER: NCT05142683.

Indexed as

COVID-19Delivery of Health Care, IntegratedDepressionDepressive DisorderAdolescentCost-Benefit AnalysisFemaleHumansMaleNon-Randomized Controlled Trials as TopicQuality-Adjusted Life YearsSARS-CoV-2AdolescentDepression & mood disordersHEALTH ECONOMICSProtocols & guidelines

Identifiers

PMID40379352
PMCPMC12083429

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.